

# company announcement

## Novo Nordisk A/S – Share repurchase programme

**Bagsværd, Denmark, 5 May 2020** – On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme, initiated 5 February 2020, Novo Nordisk has repurchased B shares for an amount up to DKK 2.9 billion in the period from 5 February 2020 to 4 May 2020. The programme is now concluded.

Since the announcement as of 27 April 2020, the following transactions have been made:

	<b>Number of B shares</b>	<b>Average purchase price</b>	<b>Transaction value, DKK</b>
<b>Accumulated, last announcement</b>	<b>6,465,000</b>		<b>2,636,088,254</b>
27 April 2020	110,000	448.14	49,295,283
28 April 2020	115,000	450.53	51,810,781
29 April 2020	115,000	436.31	50,175,726
30 April 2020	115,000	434.71	49,991,124
1 May 2020	115,000	432.61	49,750,114
4 May 2020	29,719	433.68	12,888,562
<b>Accumulated under the programme</b>	<b>7,064,719</b>		<b>2,899,999,844</b>

The details for each transaction made under the share repurchase programme are published on [novonordisk.com](http://novonordisk.com).

With the transactions stated above, Novo Nordisk owns a total of 7,093,553 B shares of DKK 0.20, corresponding to 0.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,350,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 4 May 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 7,064,719 B shares at an average share price of DKK 410.49 per B share equal to a transaction value of DKK 2,899,999,844.

*Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit [novonordisk.com](http://novonordisk.com), [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#).*

### Further information

#### Media:

Anne Margrethe Hauge	+45 4442 3450	<a href="mailto:amhg@novonordisk.com">amhg@novonordisk.com</a>
Ken Inchausti (US)	+1 609 240 9429	<a href="mailto:kiau@novonordisk.com">kiau@novonordisk.com</a>

#### Investors:

Daniel Muusmann Bohsen	+45 3075 2175	<a href="mailto:dabo@novonordisk.com">dabo@novonordisk.com</a>
Valdemar Borum Svarrer	+45 3079 0301	<a href="mailto:jvls@novonordisk.com">jvls@novonordisk.com</a>
Ann Søndermølle Rendbæk	+45 3075 2253	<a href="mailto:arnd@novonordisk.com">arnd@novonordisk.com</a>
Mark Joseph Root	+45 3079 4211	<a href="mailto:mjhr@novonordisk.com">mjhr@novonordisk.com</a>
Kristoffer Due Berg (US)	+1 609 235 2989	<a href="mailto:krdb@novonordisk.com">krdb@novonordisk.com</a>